Drug Profile
Research programme: monoclonal T-cell receptors based therapeutics - Immunocore
Alternative Names: HCV-ImmTAC; Her2-ImmTAC; IMC D104C; IMC-mage1; ImmTAB; ImmTACs; ImmTAV; Islet cell-ImmTAC; MAGE-A3-ImmTACLatest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator Immunocore
- Class Anti-infectives; Antihyperglycaemics; Antineoplastics; Antituberculars; Antivirals; Recombinant fusion proteins
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Hepatitis C; Tuberculosis
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 28 Apr 2022 No recent reports of development identified for research development in Autoimmune-disorders in United Kingdom
- 28 Dec 2021 No recent reports of development identified for preclinical development in Cancer in United Kingdom